Butler, James S.

Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms

Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy

RNA Interference and Gene DeliveryNanoparticle-Based Drug Delivery

Cited by 1,261

Safety and efficacy of RNAi therapy for transthyretin amyloidosis

Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine

Amyloidosis: Diagnosis, Treatment, OutcomesRNA Interference and Gene Delivery

Cited by 971

Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis

Butler, J. S., Chan, A., Costelha, S., Fishman, S., Willoughby, J. L. S., Borland, T. D., Milstein, S., Foster, D. J., Gonçalves, P., Chen, Q., et al. (2016) · Amyloid

Amyloidosis: Diagnosis, Treatment, OutcomesAlzheimer's disease research and treatments

Cited by 113

Combination therapy with a T mprss6 RNA i‐therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of β‐thalassemia intermedia

Schmidt, P. J., Racie, T., Westerman, M., Fitzgerald, K., Butler, J. S., & Fleming, M. D. (2015) · American Journal of Hematology

Iron Metabolism and DisordersHemoglobinopathies and Related Disorders

Cited by 77